Online inquiry

IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1619MR)

This product GTTS-WQ1619MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets F10&F9 gene. The antibody can be applied in Hemophilia A research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000504.4; NM_000133.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2159; 2158
UniProt ID P00742; P00740
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1619MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ909MR IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-221
GTTS-WQ4654MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-986036
GTTS-WQ1782MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ7787MR IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GS-HIV
GTTS-WQ1106MR IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABBV-8E12
GTTS-WQ14731MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SGN-19A
GTTS-WQ11729MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MK-0646
GTTS-WQ7083MR IVTScrip™ mRNA-Anti-FAP, FAP-IL2v(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA FAP-IL2v
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW